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Summary
Background The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness 
in unvaccinated populations is not known. We aimed to estimate the magnitude and timing of indirect eﬀ ects of 
PCVs on invasive pneumococcal disease.
Methods In this systematic review and meta-analysis, we searched bibliographic databases for non-randomised quasi-
experimental or observational studies reporting invasive pneumococcal disease changes following PCV introduction 
in unvaccinated populations (studies published Sept 1, 2010, to Jan 6, 2016), updating the previous systematic review 
of the same topic (studies published Jan 1, 1994, to Sept 30, 2010). Two reviewers extracted summary data by 
consensus. We used a Bayesian mixed-eﬀ ects model to account for between-study heterogeneity to estimate temporal 
indirect eﬀ ects by pooling of invasive pneumococcal disease changes by serotype and serogroup.
Findings Data were extracted from 70 studies included in the previous review and 172 additional studies, covering 
27 high-income and seven middle-income countries. The predicted mean times to attaining a 90% reduction in 
invasive pneumococcal disease were 8·9 years (95% credible interval [CrI] 7·8–10·3) for grouped serotypes contained 
in the seven-valent PCV (PCV7), and 9·5 years (6·1–16·6) for the grouped six additional serotypes contained in the 
13-valent PCV (PCV13) but not in PCV7. Disease due to grouped serotypes contained in the 23-valent pneumococcal 
polysaccharide vaccine (PPV23) decreased at similar rates per year in adults aged 19–64 years (relative risk [RR] 0·85, 
95% CrI 0·75–0·95) and 65 years and older (0·87, 0·84–0·90). However, we noted no changes in either group in 
invasive pneumococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13.
Interpretation Population childhood PCV programmes will lead, on average, to substantial protection across the 
whole population within a decade. This large indirect protection should be considered when assessing vaccination of 
older age groups.
Funding Policy Research Programme of the Department of Health, England.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Invasive pneumococcal disease due to Streptococcus 
pneumoniae infection is a major source of ill health 
worldwide, especially in children under 5 years, older 
people, and individuals with risk factors (ie, splenic 
dysfunction, heart disease, or immunodeﬁ ciency).1–4 
Childhood vaccination is recommended by WHO and is 
increasingly implemented across the world.5 The ﬁ rst 
pneumococcal conjugate vaccine (PCV) was seven-valent 
(PCV7), was licensed in 2000, and has since been replaced 
by ten-valent (PCV10) or 13-valent (PCV13) versions. In 
some countries, mostly high-income countries, the 
23-valent pneumococcal polysaccharide vaccine (PPV23) 
was introduced in adults earlier than childhood PCVs.6–9
Routine use of childhood PCVs has substantially 
changed the epidemiology of pneumococcal disease. In 
vaccinated young children, disease due to serotypes 
included in the vaccines has been reduced to negligible 
levels.10 Decreases in both disease and carriage have also 
been observed in unvaccinated groups in diﬀ erent 
countries.11–14 However, in unvaccinated population age 
groups, especially older adults, substantial residual 
disease and deaths due to serotypes covered by both 
childhood and adult vaccines remain.15,16 Also, in some 
settings, disease due to serotypes not covered by these 
vaccines has increased.17–21
In addition to childhood PCVs and adult PPV23 
programmes, the use of conjugate vaccines in healthy 
and immunocompromised adults is eﬀ ective. A 
randomised placebo-controlled trial15,22 of PCV13 use 
conducted during 2008–13 in the Netherlands among 
85 000 adults 65 years and older showed an eﬃ  cacy of 
75·0% (95% CI 41·4–90·8) against vaccine-type invasive 
pneumococcal disease, 45·6% (21·8–62·5) against all 
vaccine-type pneumonia, and 45·0% (14·2–65·3) against 
vaccine-type non-bacteraemic pneumonia. Previously, 
PCV7 showed an eﬃ  cacy of 75% (29–92) for prevention of 
invasive pneumococcal disease in HIV-infected adults in 
Malawi.23 In view of the eﬃ  cacy of PCV13 in adults,15,22 
some countries such as the USA introduced this vaccine 
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into their adult immunisation programme, in addition to 
PPV23, with authorities in the USA due to review the 
programme in 2018. By contrast, several developed 
countries have not introduced PCV13 into their adult 
immunisation programmes.16
In this systematic review and meta-analysis, we aim to 
assess the extent to which childhood pneumococcal 
vaccination aﬀ ects disease incidence in adult populations 
and the time course of this eﬀ ect when childhood 
vaccination programmes are introduced. This work is 
motivated by both the need to improve understanding of 
the full eﬀ ects of childhood programmes and the need to 
inform policy decisions on the use of PCVs or PPV23 in 
adult populations that have an eﬀ ective childhood PCV13 
programme. The ﬁ ndings should inform the existing 
immunisation policy discussions around the cost-
eﬀ ectiveness of introducing PCVs into adult immun-
isation programmes to speed up elimination of residual 
disease due to vaccine serotypes.24,25
Methods
Search strategy and selection criteria
We report this systematic review and meta-analysis in 
accordance with the PRISMA statement.26 To identify 
relevant articles, we updated a list of studies published 
between Jan 1, 1994, and Sept 30, 2010, reported by 
Davies and colleagues27 in a systematic review of indirect 
protection eﬀ ects of PCVs. We searched for additional 
English language studies in Medline, Embase, and Web 
of Science for the period between Sept 1, 2010, and 
Jan 6, 2016, and included the terms “pneumococcus or 
pneumococcal”, “vaccine or vaccination or immun isation 
or immune”, and “pneumonia or invasive or meningitis 
or carriage or colonisation”—ie, we used the same free 
text terms in the search strategy reported by Davies and 
colleagues,27 plus additional Medline and Embase subject 
headings (appendix). We supplemented these studies by 
searching the abstract book of the 9th International 
Symposium on Pneumococci and Pneumococcal Disease 
(ISPPD-9, held in Hyderabad, India on March 9–13, 
2014) for any relevant abstracts.
Because our study was an extension of an existing 
review, we did not register our study in any database. 
Studies were eligible if they were designed as non-
randomised quasi-experimental or observational studies 
with or without comparator group (eg, pre-test or post-
test, time series, multiple interrupted time series, 
population-based or laboratory-based surveillance), and 
if the population (of any age or sex) considered was not 
targeted for PCV vaccination. Studies were excluded if 
they reported disease changes in only vaccinated 
populations or if they reported either pre-PCV or post-
PCV data only.
The prespeciﬁ ed review outcomes were the change in 
incidence rates, and case counts or proportions of invasive 
pneumococcal disease for overall, vaccine-type grouped 
serotypes (seven serotypes in PCV7, ten serotypes in 
PCV10, six serotypes in PCV13 not in PCV7 [addPCV13], 
13 serotypes in PCV13, 11 serotypes in PPV23 but not in 
PCV13 [addPPV23], and 23 serotypes contained in PPV23) 
or individual serotypes.
Two independent reviewers screened the titles and 
abstracts of all identiﬁ ed publications, of which potentially 
eligible publications were further reviewed at the full text 
screening stage. The same two reviewers independently 
extracted the following information from included 
publications into a spreadsheet: study details (author[s], 
publication year, country, setting, and population), 
Research in context
Evidence before this study
Strong evidence shows that there are direct and herd immunity 
eﬀ ects of pneumococcal conjugate vaccines (PCVs). However, 
the protective eﬀ ect of existing vaccination programmes have 
not been systematically quantiﬁ ed. A previous systematic 
review focused on the seven-valent pneumococcal vaccine 
(PCV7) only, which has since been replaced by the 13-valent 
pneumococcal vaccine (PCV13) in most countries. Since 2010, 
many more countries have introduced the PCV13 vaccine. Data 
from individual studies have become available from diﬀ erent 
countries, with a wide range of programme maturity, 
vaccination schedules, and coverage.
Added value of this study
We have used data for disease changes due to serotypes covered 
by conjugate vaccines to provide quantitative estimates of the 
expected rate of development of herd immunity. Countries with 
mature PCV7 programmes allowed the evaluation of the 
long-term eﬀ ects. We showed that similar early eﬀ ects on disease 
due to the additional six serotypes in PCV13 suggest that 
long-term eﬀ ects will follow a similar course—ie, a 90% reduction 
in disease burden due to the covered serotypes among adults 
through herd immunity can be achieved within a decade of 
establishing a sustained childhood programme. Disease burden 
reduction is more rapid with higher vaccine coverage but 
variations in schedule are less important.
Implications of all the available evidence
The large indirect protection of childhood vaccinations 
programmes should be considered when assessing vaccination 
of older age groups, an issue that is pertinent in high-income 
countries, as well as informing priorities in the childhood 
programme. The evidence gap is substantial for low-income 
countries on the impact of childhood pneumococcal vaccination 
on disease in age groups not eligible to be vaccinated. Because 
these countries are increasingly undertaking childhood 
vaccination programmes, research to assess the indirect eﬀ ects 
in these settings is particularly relevant. 
See Online for appendix
Articles
www.thelancet.com/lancetgh   Vol 5   January 2017 e53
non-targeted group characteristics (eg, age, demographics, 
and comorbidities), vaccine programme characteristics 
(vaccine type, schedule, coverage, presence of a catch-up 
campaign, and years pre-vaccination and post-
vaccination), and outcome measures (incidence, counts, 
or proportions of invasive pneumococcal disease). Any 
disagreements between the two reviewers at both 
screening and data extraction stages were discussed and 
resolved by consensus.
In the absence of a standard methodological quality 
assessment tool for the types of study included in this 
review, we used an assessment tool for before–after 
studies with no control group, which graded the quality of 
studies as good, fair, or poor.28 The tool was tailored to our 
analysis by selecting seven relevant questions (appendix). 
For each question, a score of 1 was given if the individual 
study satisﬁ ed the criterion and a score of 0 otherwise. 
For grading each study, a total score of 0–2 was regarded 
as poor, 3–5 as fair, and more than 6 as good.
Data analysis
For each study and age category, we compared the 
invasive pneumococcal disease outcomes for the post-
vaccine and pre-vaccine introduction periods. Speciﬁ cally, 
we used the risk ratio (RR) per year post introduction as 
the measure of eﬀ ect, calculated as invasive 
pneumococcal disease outcome in any epidemiological 
year after the introduction of the vaccine divided by 
invasive pneumococcal disease outcome in any 
epidemiological year before the introduction of the 
vaccine. For studies that reported disease outcomes for a 
number of years before and after the introduction of the 
vaccine, we compared every post-vaccine year invasive 
pneumococcal disease outcome with every pre-vaccine 
year. The diﬀ erence between the date when post-PCV 
invasive pneumococcal disease was measured and the 
date of PCV introduction in the national programme 
gave the time since vaccination. In studies in which 
incidence was averaged for a number of years, we 
subtracted the year of vaccine introduction from the 
middle year for the period across which disease was 
measured to calculate the time since PCV introduction. 
Similarly, as in the review by Davies and colleagues,27 to 
ensure comparability of invasive pneumoccal disease 
outcomes, for studies that reported the proportion of 
invasive pneumococcal disease due to grouped serotypes 
or individual serotypes (both vaccine type [VT] and non-
vaccine type [NVT]), we used the following formula:
[%VTpost × %NVTpre] / [%VTpre × %NVTpost]
to approx imate RR. For studies that recorded zero isolates 
or cases of disease after the introduction of the vaccine, we 
added 1 to both the numerator and the denominator to 
avoid a zero estimate of RR.
To model disease changes over time, we used a random-
eﬀ ects model that accounted for possible heterogeneity 
between studies and clustering within studies (appendix). 
We then predicted the amount of time it takes to reduce 
disease through herd eﬀ ects by 50% and to near invasive 
pneumococcal disease elimination (which we deﬁ ned as 
the time it takes to reduce disease by 90%) by using the 
estimated model parameters. We conducted model 
simulations to predict disease changes within a period of 
30 years.
We also explored the eﬀ ect of PCV programme 
characteristics such as vaccine coverage, vaccine schedule 
(with booster or no booster), and the presence of a catch-
up campaign,27,29,30 country-speciﬁ c HIV prevalence,31 and 
income (deﬁ ned as low-income, middle-income, or high-
income) on indirect eﬀ ects. These covariates were 
included in a Bayesian mixed-eﬀ ects model. We 
conducted additional continental or regional and country-
speciﬁ c analyses to explore the eﬀ ect of any underlying 
source of heterogeneity on the eﬀ ect of childhood PCVs 
on herd protection. We also did a sensitivity analysis to 
eliminate studies with a fair or poor quality grade, 
because these studies were considered to be at increased 
risk of bias. Additionally, we used funnel plots to detect 
risk of publication bias.32
Figure 1: Stu dy selection
ISPPD 2014=International Symposium on Pneumococci and Pneumococcal 
Diseases 2014 conference abstracts. PCV=pneumococcal conjugate vaccine.
 5202 EMBASE 
 3393 MEDLINE 
 1720 PubMed 
 116 Web of Science 
 47 ISPPD 2014 
10 478 studies identified 
4977 excluded (duplicates) 
5501 screened for basic information
4988 excluded using abstract and title
513 potentially eligible full texts identified
 242 included in meta-analysis
 172 met inclusion criteria
 70 previous review
341 excluded 
 31 did not distinguish pre/post 
 129 did not include non-targeted groups 
 17 did not address PCV 
 35 did not distinguish vaccinated/unvaccinated 
 85 did not include data 
 17 carriage studies 
 5 early versus late 
 22 non-invasive disease 
Sept 1, 2010, to Jan 6, 2016
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
In our search, we identiﬁ ed 172 studies from 34 countries 
(27 high-income and seven middle-income) reporting 
changes in invasive pneumococcal disease (ﬁ gure 1, 
appendix). Of these, 16 (9%) reported changes in invasive 
pneumococcal disease due to vaccine serotypes only (ie, 
either grouped PCV7, addPCV13, or PCV13 serotypes); 
90 (52%) reported changes in invasive pneumococcal 
disease due to grouped and individual vaccine serotypes 
and overall disease; 60 (35%) reported changes in overall 
invasive pneumococcal disease only; and six (3%) focused 
on invasive pneumococcal disease changes due to 
speciﬁ c individual serotypes only. 57 (33%) studies 
reported serotype-speciﬁ c invasive pneumococcal disease 
changes.
In the previous systematic search by Davies and 
colleagues,27 70 studies from 11 countries reported 
invasive pneumococcal disease changes after the 
introduction of PCV7 or PCV10 into childhood 
immunisation programmes. 28 (40%) studies reported 
changes in invasive pneumococcal disease due to grouped 
PCV7 serotypes only; 30 (43%) reported changes in overall 
invasive pneumococcal disease only; 12 (17%) reported 
changes in disease due to both PCV7 serotypes and 
overall invasive pneumococcal disease; and eight (11%) 
studies reported serotype-speciﬁ c invasive pneumococcal 
disease changes.
101 (42%) of the 242 included studies were done in the 
USA (83) and Canada (18), 91 (38%) in Europe, and only 
nine (4%) in low-income or middle-income countries 
(appendix). 17 countries implemented a 2 + 1 schedule 
(two doses plus a booster), 13 implemented a 3 + 1 schedule, 
two implemented a 3 + 0 schedule, and two countries had 
unknown schedules. 242 studies were included in the 
analysis of changes in overall, grouped vaccine-serotype 
and individual serotype-speciﬁ c invasive pneumococcal 
disease (appendix).
Invasive pneumococcal disease due to serotypes included 
in PCV7 in all unvaccinated age groups signiﬁ cantly 
reduced, with little variation by individual serotype (table 1, 
ﬁ gure 2, appendix). The overall RR of change per year in 
invasive pneumococcal disease caused by PCV7 serotypes 
was 0·79 (95% credible interval [CrI] 0·75–0·81) in all age 
groups combined, translating to mean periods of 2·3 years 
(95% CrI 1·9–2·7) to attain 50% reduction in invasive 
pneumococcal disease caused by PCV7 serotypes in all 
unvaccinated age groups and 8·9 years (7·8–10·3) to attain 
a 90% reduction. A similar change was observed in adults 
65 years or older when the analysis was stratiﬁ ed by age 
group (RR 0·77, 95% CrI 0·75–0·80). When we assessed 
Relative risk 
(95% CrI) 
Years to 50% 
reduction 
(95% CrI)*
Years to 90% 
reduction 
(95% CrI)*
PCV7 serotypes
Vaccine-speciﬁ c serotypes (all age groups)
4 0·77 (0·72–0·84) 2·8 (2·0–3·8) 9·1 (7·1–12·2)
6B 0·79 (0·74–0·84) 2·7 (1·9–3·6) 9·7 (7·7–12·8)
9V 0·70 (0·66–0·77) 2·5 (2·0–3·1) 7·1 (5·9–8·8)
14 0·76 (0·69–0·85) 1·9 (0·9–3·2) 8·0 (5·9–12·6)
18C 0·79 (0·73–0·86) 4·1 (3·3–5·8) 11·1 (8·8–17·0)
19F 0·84 (0·80–0·90) 5·1 (4·1–7·0) 14·7 (11·8–22·2)
23F 0·73 (0·68–0·79) 2·7 (2·1–3·4) 8·0 (6·6–10·0)
Cross-reactive serotypes (all age groups)
6A 0·84 (0·78–0·89) 6·4 (5·0–9·3) 15·4 (11·8–23·1)
9N 1·03 (0·95–1·13) ·· ··
19A 0·97 (0·84–1·15) ·· ··
Age groups (all PCV7 serotypes)
All groups 0·79 (0·75–0·81) 2·3 (1·9–2·7) 8·9 (7·8–10·3)
<5 years 0·62 (0·55–0·70) 1·2 (0·8–1·7) 4·6 (3·9–6·0)
5–18 years 0·81 (0·72–0·91) 3·1 (1·9–4·9) 10·8 (7·5–21·1)
19–49 years 0·85 (0·76–0·96) 1·9 (0·0–3·8) 11·9 (8·0–30·0)
50–64 years 0·78 (0·73–0·85) 2·7 (2·0–3·4) 9·1 (7·5–12·2)
≥65 years 0·77 (0·75–0·80) 2·6 (2·3–3·0) 8·9 (7·9–10·3)
AddPCV13 serotypes
Vaccine-speciﬁ c serotypes (all age groups)
6A 0·87 (0·68–1·12) 0·4 (0·0–30·0) 11·9 (4·8–30·0)
1 0·76 (0·57–1·04) 2·2 (0·6–30·0) 7·8 (4·2–30·0)
3 1·03 (0·88–1·22) 30·0 (6·8–30·0) 30·0 (20·9–30·0)
5 0·59 (0·04–3·06) 0·1 (0·0–30·0) 5·7 (0·0–30·0)
7F 0·83 (0·67–1·01) 5·4 (2·9–30·0) 14·1 (7·1–30·0)
19A 0·74 (0·54–0·92) 2·9 (2·0–10·5) 7·6 (4·7–28·4)
Age groups (all addPCV13 serotypes)
All groups 0·75 (0·64–0·87) 3·6 (2·5–6·1) 9·5 (6·1–16·6)
<5 years 0·93 (0·30–2·64) 0·0 (0·0–30·0) 13·8 (0·0–30·0)
5–18 years 0·78 (0·55–1·08) 3·0 (0·0–30·0) 9·5 (4·7–30·0)
19–49 years 0·74 (0·56–0·99) 3·1 (1·5–30·0) 8·5 (4·6–30·0)
50–64 years 0·77 (0·59–0·99) 4·3 (2·4–30·0) 10·4 (5·6–30·0)
≥65 years 0·77 (0·66–0·90) 4·1 (2·6–7·4) 10·3 (6·4–20·7)
IPD
Age groups (all IPD) 
All groups 0·99 (0·96–0·99) ·· ··
<5 years 0·97 (0·91–1·01) ·· ··
5–18 years 0·97 (0·92–1·01) ·· ··
19–49 years 0·95 (0·91–0·99) ·· ··
50–64 years 0·96 (0·93–0·99) ·· ··
≥65 years 0·97 (0·95–0·99) ·· ··
CrI=credible interval. PCV=pneumococcal conjugate vaccines. PCV7=seven-valent 
PCV. AddPCV13=six serotypes in PCV13 not in PCV7. IPD=invasive pneumococcal 
disease. ··=not estimated. *Estimated from the full model including the intercept 
terms. The upper limits of 30 years are an artefact of following up disease changes 
for 30 years, suggesting that reduction will never reach 50% and 90% after this 
time period.
Table 1: Model estimates and predictions of changes in invasive 
pneumococcal disease among unvaccinated age groups after 
introduction of childhood PCV vaccination 
Articles
www.thelancet.com/lancetgh   Vol 5   January 2017 e55
disease changes due to additional serotypes included in 
the PCV13 vaccine but not in the PCV7 vaccine from the 
time when PCV13 replaced PCV7, the RR of disease 
change was 0·75 (0·64–0·87), predicting mean times to 
50% disease reduction of 3·6 years (95% CrI 2·5–6·1) and 
90% disease reduction of 9·5 years (6·1–16·6). We 
observed the same trend when grouped additional PCV13 
serotypes were analysed by age category, but there were no 
signiﬁ cant changes in children 18 years or younger (table 1, 
ﬁ gure 3, appendix). Overall invasive pneumococcal disease 
Figure 2: Changes in invasive pneumococcal disease due to grouped PCV7 serotypes since introduction of PCV7 into national immunisation programmes
PCV7=seven-valent pneumococcal conjugate vaccine. CrI=credible interval.
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was modestly but signiﬁ cantly reduced in adults older than 
18 years of age, but not in those younger than 18 years 
(table 1, appendix).
The rate of decline of invasive pneumococcal disease 
due to grouped PPV23 serotypes since PCV7 introduction 
was similar among adults aged 19–64 years and 65 years 
or older (table 2). These changes were mainly driven by 
reductions in vaccine serotypes, presumably through 
indirect protection. Comparison of the changes in 
invasive pneumococcal disease due to grouped serotypes 
Figure 3: Changes in invasive pneumococcal disease due to grouped additional PCV13 serotypes after PCV13 replaced PCV7
PCV7=seven-valent pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine. addPCV13= six serotypes in PCV13 not in PCV7. 
CrI=credible interval.
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included in PCV7 and PCV13 vaccines in adults aged 
19–64 years and 65 years or older, yielded similar changes 
in disease in the two groups (table 2). The RR of changes 
in invasive pneumococcal disease due to the additional 
six serotypes contained in PCV13, but not in PCV7 were 
similar between age groups (table 2). The 11 serotypes 
contained in PPV23 but not in PCV13 did not change 
invasive pneumococcal disease at any age (table 2). 
Disease due to serotypes not covered by existing vaccines 
(ie, serotypes not contained in PPV23 and PCV13), 
increased in adults 65 years or older (RR 1·18, 95% CrI 
1·12–1·25) but not in adults aged 19–64 years (1·18, 
0·96–1·41).
Model estimates did not signiﬁ cantly diﬀ er when studies 
were analysed by country (appendix). North American and 
European countries experienced similar changes for both 
invasive pneumococcal disease caused by PCV7 serotypes 
(RR 0·77, 95% CrI 0·73–0·81 for USA and Canada vs 0·77, 
0·73–0·82 for Europe) and invasive pneumococcal disease 
due to the additional six PCV13 serotypes (0·69, 0·51–0·90 
vs 0·77, 0·66–0·90). Model estimates did not diﬀ er when 
the analysis was conducted only for those studies that were 
graded as good (appendix). Rate of reduction in disease 
due to PCV7 serotypes was increased due to an increase in 
coverage (per percentage; RR 0·995, 95% CrI 0·989–0·998; 
appendix). We found no evidence of publication bias 
(appendix).
Discussion
In this systematic review and meta-analysis, we showed 
that childhood PCV immunisation confers signiﬁ cant 
indirect protection against invasive pneumococcal 
disease in unvaccinated population age groups due to 
vaccine serotypes. Herd immunity eﬀ ects continued to 
accumulate over time and reduced disease due to PCV7 
serotypes, for which follow-up data have generally been 
available for the longest period, with a 90% average 
reduction after about 9 years. The evidence from our 
synthesis of multicountry surveillance data shows that 
indirect protection against the additional six serotypes 
contained in PCV13 but not in PCV7 follows a similar 
pattern, which by extrapolation suggests that it will 
take a similar amount of time to achieve 90% reduction 
(near elimination). Overall invasive pneumococcal 
disease has decreased since the introduction of 
childhood immunisation programmes (appendix).
Our results show that the disease burden against which 
the PPV23 vaccine in adults is targeted might be 
substantially controlled by an eﬀ ective mature PCV 
programme in children. The results show substantial 
and similar decreases in invasive pneumococcal disease 
due to PCV vaccine serotypes in adults aged 19–64 years 
and adults aged 65 years and older. Moreover, although 
disease was replaced by serotypes not covered by both 
PPV23 and PCV13 (corroborating previous reports17–21), 
our results did not show changes in disease due to the 
additional 11 serotypes contained in PPV23 but not in 
PCV13 in either age group, providing no evidence for 
serotype replacement by any of the other PPV23 strains. 
The lack of evidence for an increase in the 11 PPV23 
types not covered in PCV13 might reﬂ ect a real biological 
phenomenon that removing the PCV13 strains does not 
advantage these serotypes. Alternatively, changes in 
PPV23 vaccination, such as an increase in PPV23 
vaccination in those most at risk populations, might have 
Relative risk 
(95% CrI), 19–64 years
Relative risk 
(95% CrI), ≥65 years
PCV7 serotypes
4 0·81 (0·63–1·04) 0·76 (0·68–0·83)
6B 0·75 (0·59–0·75) 0·80 (0·75–0·86)
9V 0·78 (0·70–1·02) 0·68 (0·63–0·73)
14 0·66 (0·44–0·90) 0·75 (0·68–0·84)
18C 0·75 (0·51–1·11) 0·78 (0·71–0·86)
19F 0·87 (0·68–1·13) 0·84 (0·79–0·90)
23F 0·72 (0·55–0·91) 0·73 (0·67–0·78)
All PCV7 serotypes 0·76 (0·67–0·86) 0·79 (0·76–0·84)
Cross-reactive serotypes
6A 0·92 (0·73–1·13) 0·83 (0·77–0·89)
9N 1·06 (0·76–1·52) 0·99 (0·93–1·11)
19A 0·87 (0·36–2·39) 0·93 (0·76–1·20)
AddPCV13 serotypes 
6A 0·68 (0·39–1·15) 0·90 (0·66–1·19)
1 0·65 (0·41–1·04) 0·81 (0·55–0·78)
3 1·11 (0·76–1·84) 1·01 (0·87–1·19)
5 0·86 (0·21–2·94) 0·24 (0·00–53·0)
7F 0·79 (0·49–1·15) 0·81 (0·63–1·08)
19A 0·76 (0·55–1·30) 0·79 (0·55–0·70)
All addPCV13 serotypes 0·75 (0·62–0·90) 0·78 (0·66–0·90)
All PCV13 serotypes 0·81 (0·71–0·90) 0·84 (0·81–0·88)
AddPPV23 serotypes
2 No data No data
8 1·04 (0·82–1·32) 1·04 (0·96–1·13)
9N 1·06 (0·76–1·52) 1·01 (0·93–1·11)
10A 0·85 (0·16–1·67) 1·00 (0·88–1·14)
11A 1·01 (0·74–1·39) 1·02 (0·94–1·11)
12F 0·89 (0·21–5·0) 1·07 (0·90–1·28)
15B 1·36 (0·01–424·1) 1·13 (0·90–1·38)
17F 0·94 (0·08–12·6) 1·15 (0·91–1·43)
20 1·02 (0·49–2·20) 1·01 (0·84–1·26)
22F No data No data
33F 1·03 (0·56–1·82) 0·95 (0·70–1·15)
All addPPV23 serotypes 1·05 (0·91–1·20) 1·02 (0·98–1·06)
All PPV23 serotypes since 
PCV7 introduction
0·85 (0·75–0·95) 0·87 (0·84–0·90)
Non (PPV23 + 6A)* 1·18 (0·96–1·41) 1·18 (1·12–1·25)
*All serotypes that are not covered by PPV23 and PCV13. CrI=credible interval. 
PCV=pneumococcal conjugate vaccines. PCV7=seven-valent PCV. PCV13=13-valent 
PCV. AddPCV13=six serotypes in PCV13 not in PCV7. PPV23=23-valent pneumococcal 
polysaccharide vaccine. addPPV23=11 serotypes in PPV23 but not in PCV13. 
Table 2: Model estimates comparing disease changes in adults 19 years 
or older 
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oﬀ ered some increased protection. We had no data to 
identify whether such an increase might have occurred. 
Although PPV23 could oﬀ er some protection among 
older adults in whom this vaccine has been mostly used, 
the amount of disease directly prevented by PPV23 is 
probably very small.
In countries with mature paediatric PCV programmes 
such as Canada, Germany, the Netherlands, the UK, and 
the USA, invasive pneumococcal disease due to PCV7 
serotypes has been nearly eliminated through indirect 
protection—ie, the average incidence of PCV7-invasive 
pneumococcal disease after nearly a decade of PCV7 use is 
less than 10 per 100 000 people.9,33–37 In these countries, 
consistent decreases in vaccine-type adult community-
acquired pneumonia (CAP) or meningitis, and non-
bacteraemic CAP,38–42 have been observed, indicating 
substantial indirect protection eﬀ ects against non-invasive 
disease from childhood vaccination. Our synthesis and 
analysis of published data conﬁ rms the near-elimination 
of PCV7-invasive pneumococcal disease due to a mature 
childhood PCV7 programme and predicts that the residual 
invasive pneumococcal disease due to the additional 
six serotypes contained in PCV13 will be halved after a 
mean period of about 3 years and nearly eradicated 
(90% reduction) after about 9 years after the introduction 
of PCV13. Reduction is more rapid with higher coverage, 
with an estimated RR of 0·95 (95% CrI 0·89–0·98) per 
10% increase in coverage. Given that countries with 
mature paediatric PCV programmes replaced PCV7 with 
PCV13 or PCV10 in 2010 or 2011, our results suggest that 
signiﬁ cant disease reduction (due to the additional 
six serotypes in PCV13) through indirect protection will be 
observed as the programme matures—ie, from the year 
2017 onwards.
Decision making on large-scale PCV13 use among 
older adults in the presence of a mature or maturing 
childhood programme should consider the evidence that 
the vaccines are eﬀ ective in adults on the one hand and 
that the problem against which they are targeted is 
disappearing due to herd immunity eﬀ ects on the other. 
In view of the very large numbers of people aged 65 years 
or older, any decision to introduce PCV13 has substantial 
resource requirements. The evidence that vaccinating 
ten birth cohorts provides 90% protection to those aged 
65 years or older emphasises the importance of 
prioritising this activity from a public health perspective. 
Whether an argument remains for introducing adult 
PCV in view of the expected near elimination of 
preventable disease from indirect protection should 
involve clinical decision making informed by cost-
eﬀ ectiveness assessments that might vary between 
countries and health-care systems.
A number of limitations to our study should be taken 
into account. First, we combined studies from diﬀ erent 
geographical regions that might diﬀ er in disease diagnostic 
methods and surveillance practices. This heterogeneity 
might have confounded our results. However, most studies 
(96%) emanated from highly industrialised nations with 
good surveillance programmes and broadly similar 
sociodemographic and socioeconomic make-up such that 
the epidemiology of pneumococcus is comparable among 
these countries. Additionally, our sensitivity analysis for 
individual countries and continents and our sensitivity 
analysis that excluded downgraded studies on the basis of 
their quality showed similar results to the overall estimates. 
Second, diﬀ erent studies recorded diﬀ erent outcome 
measures. Some studies measured disease incidences or 
cases and some studies measured the proportion of the 
population with the disease. Therefore, the use of an 
approximation formula to calculate RRs when proportions 
are given might underestimate the RR if the proportion of 
the population with non-vaccine serotype disease increased 
signiﬁ cantly, by more than 100% for example, after vaccine 
introduction. Some of the studies reported a single 
timepoint measure of disease (or an average), which does 
not capture secular trends. Finally, we did not have access 
to primary data, so we did not explicitly use the original 
form of data such as population sizes for use in binomial 
models for observed incidences. However, Thomson and 
Sharp43 showed that the use of a binomial model or 
assuming normality of the log odds or RRs, as we did in 
this analysis, predominantly yields similar results.
Despite these limitations, our systematic review of 
242 publications shows a largely consistent pattern across 
PCV serotypes that would question the merit of oﬀ ering 
PCV13 in older age groups in the presence of established 
paediatric programmes, and provides quantitative 
estimates of the expected rate of development of herd 
immunity to support policy makers. An important 
remaining question is whether the ﬁ ndings are relevant to 
low-income countries that experience the highest levels of 
invasive pneumococcal disease incidence, and bear a 
disproportionate burden of pneumococcal disease 
mortality and morbidity, and where the ecology of 
pneumococcal transmission might be very diﬀ erent. 
Because these countries are increasingly undertaking 
childhood vaccination programmes, research to assess the 
indirect eﬀ ects in these settings is particularly relevant.
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